Joseph A Lewnard1, Noga Givon-Lavi2,3, Daniel M Weinberger4, Marc Lipsitch1, Ron Dagan3. 1. Center for Communicable Disease Dynamics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 2. Pediatric Infectious Diseases Unit, Soroka University Medical Center. 3. Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel. 4. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut.
Abstract
BACKGROUND: Reductions in otitis media (OM) burden following rollout of pneumococcal conjugate vaccines (PCVs) have exceeded predictions of vaccine impact. In settings with active surveillance, reductions in OM caused by vaccine-targeted pneumococcal serotypes have co-occurred with reductions in OM caused by other pathogens carried in the upper-respiratory tract of children. To understand these changes, we investigated the progression of vaccine-targeted and non-vaccine pneumococcal serotypes from carriage to OM before and after vaccine rollout. METHODS: Nasopharyngeal carriage prevalence of pneumococcus was monitored in prospective studies of Bedouin and Jewish children <3 years old in southern Israel between 2004 and 2016. Incidence of OM necessitating middle-ear fluid culture (predominantly complex OM including recurrent, spontaneously-draining, non-responsive, and chronic cases) was monitored via prospective, population-based active surveillance. We estimated rates of pneumococcal serotype-specific progression from carriage to disease before and after rollout of PCV7/13, measured as OM incidence per carrier. We pooled serotype-specific estimates using Bayesian random-effects models. RESULTS: On average, rates of progression declined 92% (95% credible interval: 79-97%) and 80% (46-93%) for PCV7/13 serotypes among Bedouin and Jewish children <12 months old, respectively, and 32% (-58-71%) and 61% (-5-86%) among children aged 12-35m. For non-vaccine serotypes, rates of progression among Bedouin and Jewish children aged <12m declined 74% (55-85%) and 43% (4-68%), respectively. CONCLUSIONS: Vaccine-targeted and non-vaccine pneumococcal serotypes showed lower rates of progression to complex OM after rollout of PCV7/13. Early-life OM episodes historically associated with vaccine-serotype pneumococci may impact the susceptibility of children to OM progression.
BACKGROUND: Reductions in otitis media (OM) burden following rollout of pneumococcal conjugate vaccines (PCVs) have exceeded predictions of vaccine impact. In settings with active surveillance, reductions in OM caused by vaccine-targeted pneumococcal serotypes have co-occurred with reductions in OM caused by other pathogens carried in the upper-respiratory tract of children. To understand these changes, we investigated the progression of vaccine-targeted and non-vaccine pneumococcal serotypes from carriage to OM before and after vaccine rollout. METHODS: Nasopharyngeal carriage prevalence of pneumococcus was monitored in prospective studies of Bedouin and Jewish children <3 years old in southern Israel between 2004 and 2016. Incidence of OM necessitating middle-ear fluid culture (predominantly complex OM including recurrent, spontaneously-draining, non-responsive, and chronic cases) was monitored via prospective, population-based active surveillance. We estimated rates of pneumococcal serotype-specific progression from carriage to disease before and after rollout of PCV7/13, measured as OM incidence per carrier. We pooled serotype-specific estimates using Bayesian random-effects models. RESULTS: On average, rates of progression declined 92% (95% credible interval: 79-97%) and 80% (46-93%) for PCV7/13 serotypes among Bedouin and Jewish children <12 months old, respectively, and 32% (-58-71%) and 61% (-5-86%) among children aged 12-35m. For non-vaccine serotypes, rates of progression among Bedouin and Jewish children aged <12m declined 74% (55-85%) and 43% (4-68%), respectively. CONCLUSIONS: Vaccine-targeted and non-vaccine pneumococcal serotypes showed lower rates of progression to complex OM after rollout of PCV7/13. Early-life OM episodes historically associated with vaccine-serotype pneumococci may impact the susceptibility of children to OM progression.
Authors: Xiying Guan; Shangyuan Jiang; Thomas W Seale; Brooke M Hitt; Rong Z Gan Journal: Int J Pediatr Otorhinolaryngol Date: 2015-06-29 Impact factor: 1.675
Authors: Stefan Flasche; Albert Jan Van Hoek; Elizabeth Sheasby; Pauline Waight; Nick Andrews; Carmen Sheppard; Robert George; Elizabeth Miller Journal: PLoS Med Date: 2011-04-05 Impact factor: 11.069
Authors: Daniel M Weinberger; Krzysztof Trzciński; Ying-Jie Lu; Debby Bogaert; Aaron Brandes; James Galagan; Porter W Anderson; Richard Malley; Marc Lipsitch Journal: PLoS Pathog Date: 2009-06-12 Impact factor: 6.823
Authors: Alexandre C Fortanier; Roderick P Venekamp; Chantal W B Boonacker; Eelko Hak; Anne G M Schilder; Elisabeth A M Sanders; Roger A M J Damoiseaux Journal: Cochrane Database Syst Rev Date: 2014-04-02
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Mark R Alderson; Tim Murphy; Stephen I Pelton; Laura A Novotny; Laura L Hammitt; Arwa Kurabi; Jian-Dong Li; Ruth B Thornton; Lea-Ann S Kirkham Journal: Int J Pediatr Otorhinolaryngol Date: 2019-12-18 Impact factor: 1.675
Authors: M Wasserman; A Lucas; D Jones; M Wilson; B Hilton; A Vyse; H Madhava; A Brogan; M Slack; R Farkouh Journal: Epidemiol Infect Date: 2018-07-17 Impact factor: 4.434